- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07570316
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease (VitaliThy)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.
The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment.
The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment.
More information can be found here: https://clinicaltrials.argenx.com/vitalithy
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Sabine Coppieters, MD
- Telefonnummer: 857-350-4834
- E-post: clinicaltrials@argenx.com
Studiesteder
-
-
California
-
Carlsbad, California, Forente stater, 92012
- Rekruttering
- Profound Research LLC at Tri-City Primary Care
-
Ta kontakt med:
- Jamil Alkhaddo, MD
- Telefonnummer: 419-681-0637
- E-post: jamil.alkhaddo@profoundresearch.com
-
Orange, California, Forente stater, 92868
- Rekruttering
- Diabetes Associates Medical Group
-
Ta kontakt med:
- Ivy-Joan Madu, MD
- Telefonnummer: 714-202-8894
- E-post: diabetesmd@sbcglobal.net
-
Pasadena, California, Forente stater, 91101
- Rekruttering
- Pasadena Clinical Trials
-
Ta kontakt med:
- Tzu-Jen Tzao
- Telefonnummer: 5206127860
- E-post: ttzao@pasadenatrials.com
-
Pasadena, California, Forente stater, 91105
- Rekruttering
- Havana Research Institute LLC.
-
Ta kontakt med:
- John De Beixedon, MD
- Telefonnummer: 626-698-9794
- E-post: drjohn@havanaresearchinstitute.com
-
San Jose, California, Forente stater, 95128
- Rekruttering
- San Jose Clinical Trials
-
Ta kontakt med:
- Richard Cherlin
- Telefonnummer: 408-358-2663
- E-post: rcherlin@sanjosetrials.com
-
-
Florida
-
Fleming Island, Florida, Forente stater, 32003
- Rekruttering
- Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park Location
-
Ta kontakt med:
- Senan Sultan, MD
- Telefonnummer: 478-319-7900
- E-post: drsultan@nerifl.com
-
Fort Lauderdale, Florida, Forente stater, 33312
- Rekruttering
- The Center for Diabetes and Endocrine Care
-
Ta kontakt med:
- Sam Lerman, MD
- Telefonnummer: 954-963-7100
- E-post: slerman@diabetes-endocare.com
-
Jacksonville, Florida, Forente stater, 32256
- Rekruttering
- University of Florida Jacksonville College of Medicine
-
Ta kontakt med:
- Christian Koch
- Telefonnummer: +1 857-350-4834
- E-post: Christian.Koch@jax.ufl.edu
-
Kissimmee, Florida, Forente stater, 34744
- Rekruttering
- Ilumina Medical Research LLC
-
Ta kontakt med:
- Max Sosa-Pagan, MD
- Telefonnummer: 857-350-4834
- E-post: MSosapaganMD@gmail.com
-
Miami, Florida, Forente stater, 33144
- Rekruttering
- Oceane 7 Medical & Research Center, Inc
-
Ta kontakt med:
- Orlando Fernandez
- Telefonnummer: 305 261 2738
- E-post: o.fernandez.oceane7@gmail.com
-
-
Kansas
-
Lenexa, Kansas, Forente stater, 66219
- Rekruttering
- Johnson County Clin-Trials, Inc.
-
Ta kontakt med:
- Thomas Kreamer, MD
- Telefonnummer: 913-825-4400
- E-post: tkreamer@jcct.com
-
Wichita, Kansas, Forente stater, 67226
- Rekruttering
- Alliance for Multispecialty Research, LLC
-
Ta kontakt med:
- Terry Klein
- Telefonnummer: 316-689-6629
- E-post: terry.klein@amr-clinical.com
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan
-
Ta kontakt med:
- Tae-Hwa Chun
- Telefonnummer: 734-615-5420
- E-post: taehwa@med.umich.edu
-
Dearborn, Michigan, Forente stater, 48126
- Rekruttering
- Metro Detroit Endocrinology Center
-
Ta kontakt med:
- Ayman Elkadry, MD
- Telefonnummer: 313-203-5300
- E-post: aymankad73@gmail.com
-
Farmington Hills, Michigan, Forente stater, 48334
- Rekruttering
- Profound Research
-
Ta kontakt med:
- Gary Edelson, MD
- Telefonnummer: 947-254-1920
- E-post: gary.edelson@profoundresearch.io
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64108
- Rekruttering
- Truman Medical Center
-
Ta kontakt med:
- Rajib Bhattacharya, MD
- Telefonnummer: +1 857-350-4834
- E-post: rajib.bhattacharya@uhkc.org
-
-
New York
-
Albany, New York, Forente stater, 12203
- Rekruttering
- Albany Medical College Community Endocrinology
-
Ta kontakt med:
- Robert Busch
- Telefonnummer: 518 489 4704
- E-post: thyroiddoc@aol.com
-
New York, New York, Forente stater, 10016
- Rekruttering
- Endocrine Associates of West Village PC
-
Ta kontakt med:
- Anastasios Manessis, MD
- Telefonnummer: 646-660-9991
- E-post: amanessis@endocrinenyc.com
-
-
North Carolina
-
Asheville, North Carolina, Forente stater, 28803
- Rekruttering
- Asheville Clinical Research
-
Ta kontakt med:
- Lauren Bernstein
- Telefonnummer: +1 857-350-4834
- E-post: bbernstein@ashevilleclinicaltrials.com
-
Raleigh, North Carolina, Forente stater, 27612
- Rekruttering
- Wake Internal Medicine Consultants
-
Ta kontakt med:
- Juman Takeddin, MD
- Telefonnummer: 919-781-7500
- E-post: jtakeddin@wakeinternalmedicine.com
-
-
Texas
-
Dallas, Texas, Forente stater, 75231
- Rekruttering
- Research Institute of Dallas
-
Ta kontakt med:
- Heidi Shea, MD
- Telefonnummer: 927-867-4658
- E-post: hshea@eadallas.com
-
El Paso, Texas, Forente stater, 79935
- Rekruttering
- Frontier Medical Center - Academy of Diabetes Thyroid and Endocrine
-
Ta kontakt med:
- Sergio Rovner
- Telefonnummer: 915-633-9387
- E-post: sergiorovner@hotmail.com
-
Houston, Texas, Forente stater, 77040
- Rekruttering
- Juno Research
-
Ta kontakt med:
- Damaris Vega, MD
- Telefonnummer: 713-779-5494
- E-post: Dvega@jcct.com
-
Houston, Texas, Forente stater, 77089
- Rekruttering
- Clinic of Endocrinology
-
Ta kontakt med:
- Amir Hassan, MD
- Telefonnummer: 281-944-3610
- E-post: amir@biopharmainfo.net
-
Irving, Texas, Forente stater, 75039
- Rekruttering
- Tekton Research Irving
-
Ta kontakt med:
- Pablo Mora, MD
- Telefonnummer: 972-566-7799
- E-post: pablo.mora@tektonresearch.com
-
McAllen, Texas, Forente stater, 78503
- Rekruttering
- Biopharma Informatic, LLC
-
Ta kontakt med:
- Gloria Ortiz, MD
- Telefonnummer: 281-944-3610
- E-post: gortiz@biopharmainfo.net
-
McKinney, Texas, Forente stater, 75069
- Rekruttering
- Tekton Research - McKinney
-
Ta kontakt med:
- Muhammad Siddiqui, MD
- Telefonnummer: 972-777-6011
- E-post: muhammad.siddiqui@tektonresearch.com
-
Mesquite, Texas, Forente stater, 75149
- Rekruttering
- Southern Endocrinology Associates PA
-
Ta kontakt med:
- Sumana Gangi, MD
- Telefonnummer: 214-909-8904
- E-post: sumana_gangi@yahoo.com
-
Shavano Park, Texas, Forente stater, 78231
- Rekruttering
- Consano Clinical Research
-
Ta kontakt med:
- Daniel Katselnik, MD
- Telefonnummer: 210-545-4900
- E-post: katselnik.md@consanosa.com
-
-
-
-
-
Tbilisi, Georgia, 0114
- Rekruttering
- New Hospitals
-
Ta kontakt med:
- Lia Katcharava, MD
- Telefonnummer: +995 599530278
- E-post: likakatcharava@yahoo.com
-
Tbilisi, Georgia, 0102
- Rekruttering
- LLC American Hospital Network
-
Ta kontakt med:
- Nino Gabidzashvili, MD
- E-post: endo.advice@gmail.com
-
Tbilisi, Georgia, 0119
- Rekruttering
- LLC Todua Clinic
-
Ta kontakt med:
- Tamar Khutsishvili, MD
- E-post: Khutsishvilitamar1@outlook.com
-
Tbilisi, Georgia, 0112
- Rekruttering
- LTD Israeli-Georgian Medical Research Clinic Healthycore
-
Ta kontakt med:
- Miranda Baratashvili, MD
- E-post: baratashvilimiranda@gmail.com
-
Tbilisi, Georgia, 0159
- Rekruttering
- In Vitro Fertilization Center LLC
-
Ta kontakt med:
- Tea Khurodze, MD
- E-post: khurodze@yahoo.com
-
-
-
-
Tyne and Wear
-
Gateshead, Tyne and Wear, Storbritannia, NE9 6SX
- Rekruttering
- Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)
-
Ta kontakt med:
- Syed Salman Razvi
- Telefonnummer: +44 191 445 6052
- E-post: salman.razvi@newcastle.ac.uk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.
- Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels >=ULN (upper limit of normal) at screening.
- Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) <0.1 mIU/L at screening.
- Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening.
Exclusion Criteria:
- History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter).
- History of RAI (radioactive iodine) therapy or received a total thyroidectomy.
- T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received <6 weeks before screening.
- Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications.
- Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part A - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period. |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
|
Placebo komparator: Part A - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period. |
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS) |
|
Eksperimentell: Part B - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period. |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
|
Eksperimentell: Part B - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period. |
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS) |
|
Eksperimentell: Part C - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Tidsramme: Up to 24 weeks (part A)
|
Free triiodothyronine: [fT3]; free thyroxine: [fT4]; ATDs: antithyroid drugs |
Up to 24 weeks (part A)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to becoming euthyroid
Tidsramme: Up to 24 weeks (part A) + up to 135 weeks
|
Up to 24 weeks (part A) + up to 135 weeks
|
|
|
Efgartigimod serum concentrations over time
Tidsramme: Up to 24 weeks (part A) + 72 weeks (part C)
|
Up to 24 weeks (part A) + 72 weeks (part C)
|
|
|
Time to becoming euthyroid off ATDs in part A
Tidsramme: Up to 24 weeks (part A)
|
ATDs: antithyroid drugs |
Up to 24 weeks (part A)
|
|
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A
Tidsramme: Up to 24 weeks (part A)
|
MMI: methimazole (also known as thiamazole); CBZ: carbimazole. |
Up to 24 weeks (part A)
|
|
Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A
Tidsramme: Up to 24 weeks (part A)
|
ULN : upper limit of normal; ATDs: antithyroid drugs. |
Up to 24 weeks (part A)
|
|
Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A
Tidsramme: Up to 24 weeks (part A)
|
TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs. |
Up to 24 weeks (part A)
|
|
Time to becoming euthyroid off ATDs and TRAb seronegative
Tidsramme: Up to 24 weeks (part A) + up to 135 weeks
|
ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies. |
Up to 24 weeks (part A) + up to 135 weeks
|
|
Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)
Tidsramme: Up to 24 weeks (Part A)
|
ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole. |
Up to 24 weeks (Part A)
|
|
Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)
Tidsramme: Up to 24 weeks (part A)
|
TSH: thyroid-stimulating hormone; LLN: lower limit of normal. |
Up to 24 weeks (part A)
|
|
Percentage of participants who remain euthyroid without ATDs
Tidsramme: Up to 74 weeks (part B)
|
ATDs: antithyroid drug |
Up to 74 weeks (part B)
|
|
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months
Tidsramme: Up to 74 weeks (part B) + up to 135 weeks
|
ATDs: antithyroid drug |
Up to 74 weeks (part B) + up to 135 weeks
|
|
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS
Tidsramme: Up to 72 weeks (part C)
|
ATDs: antithyroid drug |
Up to 72 weeks (part C)
|
|
Incidence of AEs and SAEs
Tidsramme: Up to 135 weeks
|
AEs: adverse events ; SAEs: serious adverse events. |
Up to 135 weeks
|
|
Change in ThyPRO-39 over time
Tidsramme: Up to 135 weeks
|
The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status. |
Up to 135 weeks
|
|
Change in PROMIS-PF10a over time
Tidsramme: Up to 135 weeks
|
The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function. |
Up to 135 weeks
|
|
Percentage change from baseline in total IgG levels in serum over time
Tidsramme: Up to 98 weeks
|
IgG: immunoglobulin G |
Up to 98 weeks
|
|
Percentage change from baseline in TRAb serum levels over time
Tidsramme: Up to 135 weeks
|
TRAb: anti-TSHR autoantibodies. |
Up to 135 weeks
|
|
Incidence of ADA against efgartigimod in serum
Tidsramme: Up to 24 weeks (part A) + up to 135 weeks
|
ADA: antidrug antibody(ies) |
Up to 24 weeks (part A) + up to 135 weeks
|
|
Incidence of antibodies against rHuPH20 in plasma
Tidsramme: Up to 24 weeks (part A) + Up to 135 weeks
|
rHuPH20: recombinant human hyaluronidase PH20 |
Up to 24 weeks (part A) + Up to 135 weeks
|
|
Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma
Tidsramme: Up to 24 weeks (part A) + up to 135 weeks
|
NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20. |
Up to 24 weeks (part A) + up to 135 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ARGX-113-25-GRD-3002
- 2025-524223-42-00 (Ctis)
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .